RVMDW — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
| Sep 2025 | 0 | — | -315,269,000 | -305,206,000 | 2,251,920,000 | 217,442,000 | 655,016,000 |
| Jun 2025 | 0 | — | -264,714,000 | -247,787,000 | 2,429,568,000 | 402,438,000 | 564,199,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-897,741,000
Investing CF
$118,058,000
Financing CF
$621,524,000
CapEx
$-15,990,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,869,102,000
Inventory
—
Receivables
$0
ST Investments
$1,641,934,000
EBIT TTM
$-1,152,208,000
Pretax Income TTM
$-1,131,301,000
Interest Exp TTM
$23,364,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | — | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | — | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | — | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | — | -224,401,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $181.31B | $335.94 | — |
| GILD | GILEAD SCIENCES, INC. | $166.04B | $133.73 | — |
| ARGX | ARGENX SE | $50.27B | $808.43 | — |
| RVMD | Revolution Medicines, Inc. | $32.93B | $154.89 | — |
| BIIB | BIOGEN INC. | $28.51B | $193.08 | — |
News headlines (Yahoo Finance, 1h cache)
Erasca Patent Dispute Puts ERAS-0015 And Investment Case Under Scrutiny
2026-05-26 00:19 · Yahoo
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting
2026-05-22 11:46 · Yahoo
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
2026-05-21 20:05 · Yahoo
Is Daraxonrasib’s Phase 3 Pancreatic Cancer Data And EQRx Deal Altering The Investment Case For Revolution Medicines (RVMD)?
2026-05-21 07:09 · Yahoo
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
2026-05-20 12:45 · Yahoo
Needham Keeps Buy Rating on Revolution Medicines (RVMD) Despite Wider Loss
2026-05-20 07:22 · Yahoo
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
2026-05-18 20:00 · Yahoo
Another billionaire dumps mega-cap stock for AI bet
2026-05-18 02:03 · Yahoo
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
2026-05-17 20:46 · Yahoo
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
2026-05-17 20:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.